BLTE
BELITE BIO, INC
+2.29 (+1.36%)171.51USD47.6K成交股數–市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-11-09下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 42 · 32.0M · 2 |
| 其中 10b5-1 計畫賣出 | 42 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 40.5M |
| 近 180 天 淨額 | −40.5M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 6.1K | 195.62 | 1.2M | 87.6K | SEC |
| 2026-09-08 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 4.5K | 196.47 | 879K | 33.2K | SEC |
| 2026-09-08 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 4.6K | 197.23 | 908K | 28.6K | SEC |
| 2026-09-08 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 4.1K | 195.60 | 806K | 37.7K | SEC |
| 2026-09-08 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 8.8K | 197.36 | 1.7M | 72.8K | SEC |
| 2026-09-08 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 2.6K | 198.05 | 507K | 26.0K | SEC |
| 2026-09-08 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 2.7K | 198.09 | 535K | 70.1K | SEC |
| 2026-09-08 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 2.4K | 194.33 | 466K | 93.7K | SEC |
| 2026-09-08 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 2.2K | 194.28 | 427K | 41.8K | SEC |
| 2026-09-08 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 6.1K | 196.54 | 1.2M | 81.6K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 4.6K | 185.34 | 851K | 146K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 3.4K | 192.40 | 654K | 48.6K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 2.0K | 182.49 | 365K | 87.8K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 11.1K | 191.15 | 2.1M | 108K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 7.8K | 186.32 | 1.5M | 138K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 6.2K | 191.09 | 1.2M | 52.0K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 3.4K | 182.50 | 623K | 162K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 2.6K | 181.24 | 469K | 165K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 5.0K | 183.30 | 908K | 157K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 3.6K | 184.57 | 659K | 80.5K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 6.3K | 184.52 | 1.2M | 151K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 1.6K | 180.16 | 294K | 91.8K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 3.9K | 185.28 | 717K | 76.6K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 4.6K | 193.12 | 889K | 44.0K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 3.0K | 188.26 | 573K | 129K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 6.2K | 187.25 | 1.2M | 132K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 4.6K | 186.35 | 857K | 72.0K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 9.0K | 189.34 | 1.7M | 120K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 600 | 190.39 | 114K | 120K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 1.8K | 190.63 | 343K | 58.2K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 6.2K | 189.22 | 1.2M | 60.0K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 1.9K | 188.59 | 358K | 66.2K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 3.8K | 183.27 | 689K | 84.0K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 2.0K | 181.05 | 362K | 89.8K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 8.1K | 193.13 | 1.6M | 96.1K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 4.2K | 192.54 | 810K | 104K | SEC |
| 2026-09-04 | 09-09 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 2.6K | 180.29 | 475K | 168K | SEC |
| 2026-09-04 | 09-09 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 3.9K | 187.16 | 730K | 68.1K | SEC |
| 2026-08-12 | 08-14 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 144 | 180.00 | 26K | 93.7K | SEC |
| 2026-08-12 | 08-14 | Chuang Hao-Yuan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 223 | 180.57 | 40K | 93.4K | SEC |
| 2026-08-12 | 08-14 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 223 | 180.57 | 40K | 171K | SEC |
| 2026-08-12 | 08-14 | Lin Yu-Hsin | Chief Executive Officer | S 公開市場賣出(10b5-1) | 142 | 180.00 | 26K | 171K | SEC |
| 2026-06-18 | 06-22 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 96 | 143.90 | 14K | 24.9K | SEC |
| 2026-06-18 | 06-22 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 96 | 147.11 | 14K | 15.0K | SEC |
| 2026-06-18 | 06-22 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 1.2K | 146.24 | 175K | 15.1K | SEC |
| 2026-06-18 | 06-22 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 4.9K | 145.43 | 707K | 16.3K | SEC |
| 2026-06-18 | 06-22 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 3.7K | 144.66 | 542K | 21.2K | SEC |
| 2026-06-16 | 06-17 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 784 | 138.18 | 108K | 32.2K | SEC |
| 2026-06-16 | 06-17 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 2.1K | 137.61 | 283K | 32.9K | SEC |
| 2026-06-16 | 06-17 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 1.9K | 143.55 | 272K | 26.0K | SEC |
| 2026-06-16 | 06-17 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 450 | 142.20 | 64K | 27.9K | SEC |
| 2026-06-16 | 06-17 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 100 | 141.83 | 14K | 28.4K | SEC |
| 2026-06-16 | 06-17 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 540 | 140.58 | 76K | 28.5K | SEC |
| 2026-06-16 | 06-17 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 1.0K | 145.02 | 150K | 25.0K | SEC |
| 2026-06-16 | 06-17 | Scholl Hendrik Peter | Chief Medical Officer | S 公開市場賣出 | 3.1K | 139.57 | 438K | 29.0K | SEC |
| 2026-05-07 | 05-08 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 226 | 152.45 | 34K | 440 | SEC |
| 2026-05-07 | 05-08 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 3 | 154.61 | 463.83 | 9 | SEC |
| 2026-05-07 | 05-08 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 428 | 153.56 | 66K | 12 | SEC |
| 2026-05-07 | 05-08 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 9 | 155.25 | 1K | 0 | SEC |
| 2026-05-06 | 05-07 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 240 | 154.41 | 37K | 866 | SEC |
| 2026-05-06 | 05-07 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 128 | 153.42 | 20K | 1.1K | SEC |
| 2026-05-06 | 05-07 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 424 | 152.67 | 65K | 1.2K | SEC |
| 2026-05-06 | 05-07 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 8 | 151.57 | 1K | 1.7K | SEC |
| 2026-05-06 | 05-07 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 100 | 155.97 | 16K | 766 | SEC |
| 2026-05-06 | 05-07 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 100 | 156.00 | 16K | 666 | SEC |
| 2026-05-05 | 05-06 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 173 | 155.48 | 27K | 2.0K | SEC |
| 2026-05-05 | 05-06 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 363 | 154.44 | 56K | 2.2K | SEC |
| 2026-05-05 | 05-06 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 120 | 153.92 | 18K | 2.5K | SEC |
| 2026-05-05 | 05-06 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 68 | 158.11 | 11K | 1.7K | SEC |
| 2026-05-05 | 05-06 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 155 | 157.29 | 24K | 1.7K | SEC |
| 2026-05-05 | 05-06 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 121 | 156.53 | 19K | 1.9K | SEC |
| 2026-05-04 | 05-05 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 235 | 156.57 | 37K | 2.8K | SEC |
| 2026-05-04 | 05-05 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 325 | 155.21 | 50K | 3.1K | SEC |
| 2026-05-04 | 05-05 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 172 | 157.49 | 27K | 2.7K | SEC |
| 2026-05-04 | 05-05 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 236 | 154.24 | 36K | 3.4K | SEC |
| 2026-05-04 | 05-05 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 32 | 153.50 | 5K | 3.6K | SEC |
| 2026-05-01 | 05-04 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 82 | 156.24 | 13K | 3.9K | SEC |
| 2026-05-01 | 05-04 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 346 | 155.48 | 54K | 4.0K | SEC |
| 2026-05-01 | 05-04 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 288 | 154.38 | 44K | 4.3K | SEC |
| 2026-05-01 | 05-04 | MATA NATHAN L. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 52 | 153.89 | 8K | 4.6K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3.1M | 457M | 新進 | 新進 |
| Paradigm Biocapital Advisors LP | 1.2M | 190M | 新進 | 新進 |
| RTW INVESTMENTS, LP | 715K | 110M | 新進 | 新進 |
| 千禧 MILLENNIUM MANAGEMENT LLC | 495K | 76.2M | 新進 | 新進 |
| MAVERICK CAPITAL LTD | 396K | 61.0M | 新進 | 新進 |
| EVENTIDE ASSET MANAGEMENT, LLC | 391K | 60.2M | 新進 | 新進 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 357K | 55.0M | 新進 | 新進 |
| Holocene Advisors, LP | 251K | 38.7M | 新進 | 新進 |
| Logos Global Management LP | 250K | 38.5M | 新進 | 新進 |
| MORGAN STANLEY | 235K | 36.2M | 新進 | 新進 |
| UBS Group AG | 225K | 34.6M | 新進 | 新進 |
| 城堡 CITADEL ADVISORS LLC | 186K | 28.7M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 166K | 25.6M | 新進 | 新進 |
| Affinity Asset Advisors, LLC | 165K | 25.4M | 新進 | 新進 |
| MPM BIOIMPACT LLC | 137K | 21.1M | 新進 | 新進 |
| BANK OF AMERICA CORP /DE/ | 125K | 19.2M | 新進 | 新進 |
| Patient Square Capital LP | 110K | 16.9M | 新進 | 新進 |
| JANE STREET GROUP, LLC | 65.8K | 10.1M | 新進 | 新進 |
| BNP PARIBAS FINANCIAL MARKETS | 57.1K | 8.8M | 新進 | 新進 |
| 文藝復興 RENAISSANCE TECHNOLOGIES LLC | 55.8K | 8.6M | 新進 | 新進 |
| Point72(柯恩) Point72 Asset Management, L.P. | 51.2K | 7.9M | 新進 | 新進 |
| Soleus Capital Management, L.P. | 50.5K | 7.8M | 新進 | 新進 |
| Trexquant Investment LP | 49.5K | 7.6M | 新進 | 新進 |
| Two Sigma TWO SIGMA INVESTMENTS, LP | 38.1K | 5.9M | 新進 | 新進 |
| PFM Health Sciences, LP | 34.8K | 5.4M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 81 +6 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 81 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 9.5M |
| 合計季末市值 | 1.4B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 1.0M |
|---|---|
| 與上期比 | -6.0% |
| 佔流通股數 | –(外國發行人不算) |
| 日均成交量 | 142K |
| 回補天數 | 7.4 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 1.0M | -6.0% | – | 142K | 7.4 |
| 2026-08-14 | 1.1M | -1.6% | – | 191K | 5.8 |
| 2026-07-31 | 1.1M | -13.7% | – | 169K | 6.7 |
| 2026-07-15 | 1.3M | +0.1% | – | 186K | 7.1 |
| 2026-06-30 | 1.3M | -0.8% | – | 247K | 5.3 |
| 2026-06-15 | 1.3M | +10.3% | – | 238K | 5.6 |
| 2026-05-29 | 1.2M | +0.9% | – | 243K | 5.0 |
| 2026-05-15 | 1.2M | -3.4% | – | 123K | 9.7 |
| 2026-04-30 | 1.2M | +10.6% | – | 109K | 11.3 |
| 2026-04-15 | 1.1M | +6.7% | – | 159K | 7.0 |
| 2026-03-31 | 1.0M | +5.5% | – | 174K | 6.0 |
| 2026-03-13 | 991K | +25.1% | – | 187K | 5.3 |
| 2026-02-27 | 792K | +16.2% | – | 155K | 5.1 |
| 2026-02-13 | 682K | +16.5% | – | 209K | 3.3 |
| 2026-01-30 | 585K | +49.4% | – | 209K | 2.8 |
| 2026-01-15 | 392K | +18.8% | – | 291K | 1.4 |
| 2025-12-31 | 330K | +12.1% | – | 205K | 1.6 |
| 2025-12-15 | 294K | -45.3% | – | 363K | 1.0 |
| 2025-11-28 | 537K | +85.1% | – | 196K | 2.8 |
| 2025-11-14 | 290K | +6.3% | – | 104K | 2.8 |
| 2025-10-31 | 273K | +16.6% | – | 90.9K | 3.0 |
| 2025-10-15 | 234K | -0.5% | – | 60.7K | 3.9 |
| 2025-09-30 | 235K | +18.8% | – | 54.7K | 4.3 |
| 2025-09-15 | 198K | +9.8% | – | 46.1K | 4.3 |
| 2025-08-29 | 180K | -4.6% | – | 35.5K | 5.1 |
| 2025-08-15 | 189K | +11.6% | – | 59.6K | 3.2 |